What Peer-Reviewed Muse Cell Evidence Means for Investigational Cell Therapy at Springs Rejuvenation
Aventura, United States - October 24, 2026 / Springs Rejuvenation /
Springs Rejuvenation has published a patient-focused educational review summarizing the peer-reviewed literature on Muse cell research, drawing from two Japanese clinical studies and one intravenous mesenchymal stem cell (MSC) safety trial, as the clinic's physician team continues to refine its Stem 3 Protocol across five US locations in New York City, Los Angeles, Austin, Miami, and Atlanta.
What the Published Literature Shows - and Does Not Yet Show
The review centers on three studies that represent some of the most closely watched data in muse stem cell research to date. The first is a first-in-human Japanese safety study published by Noda and colleagues in 2020, which evaluated the administration of Muse cells in human subjects and reported no serious adverse events attributable to the cells during the observation period. Researchers noted the findings as an early signal warranting further investigation, not a demonstration of efficacy. The study did not meet statistically significant endpoints for clinical improvement, and its authors framed the results as preliminary safety data only.
The second study, a randomized double-blind Japanese trial published by Niizuma and colleagues in 2023, provided more controlled muse cell evidence but similarly returned modest endpoint results. The randomized design strengthened confidence in the safety profile observed, while the efficacy data remained inconclusive at the measured intervals. Researchers in that trial acknowledged the need for larger cohorts and longer follow-up windows before broader conclusions could be drawn.
The third reference point is a 2009 intravenous MSC safety trial by Hare and colleagues, which evaluated the systemic administration of mesenchymal stem cells and reported an acceptable safety profile in the study population. That data has since informed how clinicians approach cell delivery in investigational cell therapy contexts, though it predates the specific Muse cell characterization literature and involves a distinct cell population.
Dr. Charles Pereyra, MD on Reading the Evidence Carefully
Springs Rejuvenation's protocols are overseen by Dr. Charles Pereyra, MD, a board-certified emergency medicine physician who completed his residency at NewYork-Presbyterian Brooklyn Methodist Hospital, holds membership in the International Society of Hair Restoration Surgery (ISHRS), and has three published papers indexed on PubMed (NPI 1932553900). His clinical perspective shapes how the clinic contextualizes published data for patients.
"What we find in the published muse cell clinical trials is that the safety signals are encouraging but the efficacy picture is still forming," said Dr. Charles Pereyra, MD of Springs Rejuvenation. "Our role is to be transparent with patients about what the data does and does not yet demonstrate, and to operate within a physician-supervised framework that reflects that honest read of the science."
How the Stem 3 Protocol Reflects the Current Evidence Base
Springs Rejuvenation's Stem 3 Protocol pairs stem cells with exosomes, a combination the clinic uses in recognition of the complementary roles each component may help support in cellular signaling environments. The protocol incorporates a 0.9mm micro FUE procedure step for applicable applications, performed under physician-supervised US-based care at each of the five clinic locations. All procedures are conducted by or under the direct oversight of licensed medical professionals, consistent with the clinic's position that investigational approaches require active clinical supervision rather than delegated administration.
The clinic's patient education materials now reference the Noda 2020, Niizuma 2023, and Hare 2009 studies by name, with explicit acknowledgment of where null results or modest endpoints were reported. Springs Rejuvenation has stated that its educational posture is to present what peer-reviewed findings may help support in terms of safety understanding, while refraining from claims that outpace the current state of the literature.
About Springs Rejuvenation
Springs Rejuvenation operates five physician-supervised clinics across the United States, located in New York City, Los Angeles, Austin, Miami, and Atlanta. The practice focuses on investigational cell therapy approaches that pair stem cells with exosomes, guided by board-certified medical oversight and an ongoing review of published research. Dr. Charles Pereyra, MD leads the clinical team and brings emergency medicine board certification, ISHRS membership, and peer-reviewed publication experience to the practice.
Our Stem Cell exosome formula is produced in an FDA approved lab, but is not an FDA approved therapy. It is currently in the experimental stages - all information provided is based on our experience with patients. Results may vary. Consult with a qualified medical professional.
Learn more at Springs Rejuvenation
Contact Information:
Springs Rejuvenation
245 5th Ave 3rd Floor Suite 307
Aventura, Florida 10016
United States
Charles Pereyra
(305) 363-0718
https://home.springsrejuvenation.com
